Scholarlink

<p>To assess N-Terminal Pro C-Type Natriuretic Peptide (NT-proCNP) plasma levels in patients with chronic obstructive pulmonary disease (COPD) and evaluate of its diagnostic value for pulmonary hypertension (PH) in COPD. According to the range of systolic pulmonary artery pressure (SPAP), the COPD patients were divided into group of patients without PH (SPAP &lt; 40 mmHg, <i>n</i> = 42) and group of patients with PH (SPAP ≥40 mmHg, <i>n</i> = 52). Significant differences in NT-proCNP levels were found in patients with and without PH (3.63 ± 0.95 pg/mL vs. 1.42 ± 0.35 pg/mL, <i>p</i> &lt; 0.001). Statistically significant correlations were shown between NT-proCNP levels and SPAP (<i>r</i> = 0.77, <i>p</i> &lt; 0.001), mMRC dyspnea score (<i>r</i> = 0.42, <i>p</i> = 0.001), CAT score (<i>r</i> = 0.60, <i>p</i> &lt; 0.001), and SpO<sub>2</sub> (<i>r</i> = − 0.47, <i>p</i> = 0.001). Pulmonary hypertension in COPD patients was associated with higher plasma NT-proCNP levels.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

NT-proCNP as a new biomarker of pulmonary hypertension in patients with COPD

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月1日

查看全文
  • Sergey N. Avdeev,
  • Viliya V. Gaynitdinova,
  • Zamira M. Merzhoeva,
  • Galiya S. Nuralieva,
  • Evgeniy A. Tarabrin,
  • Zelimkhan G. Berikkhanov,
  • Lidiya Y. Nikitina,
  • Tatiana Y. Gneusheva,
  • Elizaveta S. Sokolova,
  • Rifat M. Ainetdinov,
  • Anna A. Proshkina,
  • Kirill S. Ataman,
  • Qingyun Ma

摘要

To assess N-Terminal Pro C-Type Natriuretic Peptide (NT-proCNP) plasma levels in patients with chronic obstructive pulmonary disease (COPD) and evaluate of its diagnostic value for pulmonary hypertension (PH) in COPD. According to the range of systolic pulmonary artery pressure (SPAP), the COPD patients were divided into group of patients without PH (SPAP < 40 mmHg, n = 42) and group of patients with PH (SPAP ≥40 mmHg, n = 52). Significant differences in NT-proCNP levels were found in patients with and without PH (3.63 ± 0.95 pg/mL vs. 1.42 ± 0.35 pg/mL, p < 0.001). Statistically significant correlations were shown between NT-proCNP levels and SPAP (r = 0.77, p < 0.001), mMRC dyspnea score (r = 0.42, p = 0.001), CAT score (r = 0.60, p < 0.001), and SpO2 (r = − 0.47, p = 0.001). Pulmonary hypertension in COPD patients was associated with higher plasma NT-proCNP levels.